Oxford Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Oxford Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06M	Buy	+39,090	New	+$1.61M	0.89%	13
2025 Q2	–	Sell	-33,027	Closed	-$91.2K	–	758
2025 Q1	$91.2K	Buy	33,027 +17,571	+114%	+$71.8K	0.04%	425
2024 Q4	$85.6K	Buy	+15,456	New	+$105K	0.04%	403
2024 Q3	–	Sell	-14,689	Closed	-$100K	–	446
2024 Q2	$100K	Buy	+14,689	New	+$89K	0.1%	235

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Oxford Asset Management's TERN Position: Q1 2026 in Review

Oxford Asset Management opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 39,090 shares worth $2.06M. The stake represents 0.89% of the portfolio and ranks #13 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in TERN as recently as Q1 2025.

Oxford Asset Management first reported a position in TERN in Q2 2024 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Oxford Asset Management held 39,090 shares of Terns Pharmaceuticals worth $2.06M as of Q1 2026.
Terns Pharmaceuticals was a new Oxford Asset Management position in Q1 2026.
Terns Pharmaceuticals made up 0.89% of Oxford Asset Management's portfolio in Q1 2026, its #13 holding.
Oxford Asset Management first reported a position in Terns Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.